Product/Composition:- | Ceftazidime Powder for Solution |
---|---|
Strength:- | 1 g, 2 g, 2.5 g, 3 g, 4 g |
Form:- | Powder for Solution |
Reference Brands:- | Fortaz, Tazicef(US& EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ceftazidime suspension inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It is effective against gram-negative bacteria, including Pseudomonas aeruginosa. Benefits include targeted, reliable oral therapy for pediatric or outpatient infections, rapid bacterial clearance, broad-spectrum activity, and convenience in managing serious infections in children.
Ceftazidime suspension is approved in the EU and US for treating severe gram-negative bacterial infections, particularly in pediatric patients. In the EU, brands like Fortaz and generics are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on comprehensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality standards, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ceftazidime suspension, ensuring adherence to European and US standards for safe, effective therapy in serious infections.